Arcellx is a biotechnology company reimagining cell therapy through the development of immunotherapies. Co.'s D-Domain powered autologous and allogeneic Chimeric Antigen Receptor T cells (CAR-Ts) includes classical single infusion CAR-Ts (ddCARs) and dosable and controllable universal CAR-Ts (ARC-SparX), to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. Co.'s main ddCAR product candidate, CART-ddBCMA, is for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). Co. is developing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia and myelodysplastic syndrome. The ACLX average annual return since 2022 is shown above.
The Average Annual Return on the ACLX average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACLX average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACLX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|